[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"house-dust-mite-allergy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:house-dust-mite-allergy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100637208","bhlmann-bat-basophil-activation-test-in-allergy-diagnosis-exploratory-pilot-study-100637208",false,"NCT07596303","BÜHLMANN BAT (Basophil Activation Test) in Allergy Diagnosis (Exploratory Pilot Study)","Exploratory Pilot Study of BÜHLMANN Automated Basophil Activation Test as an Aid to Diagnosis of Immediate Type Allergic Disorders","Inclusion Criteria:\n\n* Individuals with diagnosis of a hypersensitivity \u002F allergy to one of the 6 allergens, established according to common clinical practice\n\nExclusion Criteria:\n\n* Pregnant women\n* Children under the age of 18 months\n* Individuals under therapy with Omalizumab or Rituximab\n* Individuals with an allergic reaction less than two weeks before blood sample collection\n* Individuals under therapy with BTK inhibitors\n* Individuals receiving allergen specific immunotherapy (ASIT)\n* Subjects with active infection and inflammatory conditions\n* Patients who are unable to understand the study information and informed consent form in German","ALL","18 Months",{"count":19,"type":20},60,"ESTIMATED","OBSERVATIONAL","The goal of this exploratory pilot study is to generate early data needed for future validation studies of the automated BÜHLMANN BAT (Basophil activation test) assay. The main questions it aims to answer are:\n\nDoes the BAT assay use the optimal allergen concentrations for stimulation, and how do its preliminary cut-offs perform in a real-world clinical scenario?\n\nParticipants older than 1.5 years who are being evaluated for possible allergy sensitization will provide one additional blood tube during their routine blood draw as part of the regular medical care. The study involves only one visit and does not provide direct personal benefit.",[24,25,26,27,28,29],"Allergy Testing","Peanut Allergies","Venom Allergy","House Dust Mite Allergy","Hazelnut Allergy","Cat Epithelium Allergy","RECRUITING","2026-05-28",{"date":33,"type":34},"2026-06-01","ACTUAL",{"date":36,"type":20},"2026-05",{"date":38,"type":20},"2026-08-31",{"name":40,"class":41},"Bühlmann Laboratories AG","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100469659","phase-3-efficacy-and-safety-assessment-of-beltavac-with-polymerized-extract-of-hdm-100469659","NCT05395689","Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM","Efficacy and Safety Assessment of a Subcutaneous Immunotherapy (Beltavac®) With Polymerized Allergenic Extract From House Dust Mites in Patients With Allergic Rhinitis\u002FRhinoconjuntivitis","PROACAROS","Inclusion Criteria:\n\n* Written informed consent, signed and duly dated.\n* Man or woman between 12 and 65 years old (both included).\n* Patient with moderate or severe symptoms of persistent rhinitis according to the ARIA Guide, associated or not with well or partially controlled asthma according to the GEMA 5.0 Guide.\n* Confirmation of sensitization to DPT or DF with a positive prick test (mean papule diameter greater than or equal to 3 mm) with a commercial standardized allergenic extract and a serum extract-specific IgE value of class 3 or higher (\\> 3.5 kU \u002F L) within the 6 months prior to the study.\n* Negative pregnancy test.\n* Nasal symptom and medication combined scale score ≥ 1.5 during the screening phase.\n\nExclusion Criteria:\n\n* Concomitant sensitization to allergens other than dust mites if clinically relevant symptoms are anticipated that may interfere with study evaluation periods at the discretion of the investigator.\n* Poorly controlled asthma according to the GEMA 5.0 guideline\n* Severe asthma, that is, those who during the last months have controlled their asthma according to therapeutic step 5-6 of the GEMA 5.0 guideline.\n* Autoimmune diseases or immunodeficiency.\n* Malignant neoplasms, serious cardiovascular disease, serious mental illness or other relevant chronic diseases that may interfere with the results of the study.\n* Clinical history of anaphylaxis with cardio \u002F respiratory symptoms.\n* Hypersensitivity to any of the excipients of the investigational product.\n* Immunosuppressive medication during the last 6 months before the inclusion of patients and until the end of the study.\n* Treatment with beta-blockers during the study.\n* Patients who have previously received immunotherapy with allergenic dust mite extract or other extracts and have failed within the last 5 years.\n* Patients with immunotherapy with allergens other than dust mites during the study period.\n* Patients who receive any other vaccine one week before the start of treatment or awaiting the second dose of vaccine against COVID-19.\n* Pregnant or nursing patients.","12 Years","65 Years",{"count":54,"type":20},350,"INTERVENTIONAL",[57],"PHASE3","The trial is performed to assess efficacy and safety of Beltavac with polymerized extract of house dust mites in allergic Rhinoconjunctivitis associated or not with asthma",[27],"2024-07-17",{"date":62,"type":34},"2024-07-18",{"date":64,"type":34},"2022-01-17",{"date":66,"type":20},"2026-06",{"name":68,"class":41},"Probelte Pharma S.L.U.",18]